Corticosteroids

Acarbose, corticosteroids

The combined active ingredient with acarbose may cause hyperglycaemia, what may attenuate the acarbose effects. Monitorization of the blood-sugar concentration is recommended

ACE inhibitors, corticosteroids

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leucopenia.

Aceclofenac [1], corticosteroids ---> SmPC of [1] of eMC

Increased risk of gastrointestinal ulceration or bleeding

Acemetacine, corticosteroids

Increased risk of gastrointestinal ulceration or bleeding.

Acenocoumarol, corticosteroids

Corticosteroids may enhance the anticoagulant effect of acenocoumarol

Acetylsalicylic acid [1], corticosteroids ---> SmPC of [1] of eMC

The co-administration may increase the risk of gastrointestinal bleeding and ulceration

Adrenaline [1], corticosteroids ---> SmPC of [1] of eMC

Drugs which cause potassium loss (corticosteroids, potassium-depleting diuretic, aminophylline, theophylline) increase the risk of hypokalemia.

Alfacalcidol, corticosteroids

There is a functional antagonism between vitamin D analogues (promotion of absorption) and the corticosteroids (inhibition of absorption).

Aliskiren/hydrochlorothiazide [1], corticosteroids ---> SmPC of [1] of EMA

The potassium-depleting effect of hydrochlorothiazide on serum potassium would be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia

Aminophylline, corticosteroids

There is an increased risk of hypokalaemia when theophylline derivatives are given with corticosteroids

Amiodarone [1], corticosteroids ---> SmPC of [1] of eMC

Caution should be exercised over combined therapy with drugs which may also cause hypokalaemia and/or hypomagnesaemia

Amlodipine/valsartan/hydrochlorothiazide [1], corticosteroids ---> SmPC of [1] of EMA

The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of corticosteroids. If these medicines are to be prescribed with amlodipine/valsartan/hydrochlorothiazide, monitoring of potassium plasma levels is advised.

Amphetamine, corticosteroids

Amfetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.

Amphotericin, corticosteroids

Increased risk of hypokalaemia with amphotericin.

Amprenavir/ritonavir, corticosteroids primarily metabolised by CYP3A ---> SmPC of [amprenavir] of EMA

Concomitant use of Agenerase with ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects

Anticoagulants, corticosteroids ---> SmPC of [deflazacort] of eMC

Corticosteroids may increase or decrease the effects of anticoagulant drugs

Antihypertensives, corticosteroids

The desired effects of antihypertensives are antagonized by corticosteroids

Ataluren [1], corticosteroids ---> SmPC of [1] of EMA

Coadministration of corticosteroids (deflazacort, prednisone, or prednisolone) with ataluren did not affect the plasma concentrations of ataluren.

Atazanavir/cobicistat [1], corticosteroids primarily metabolised by CYP3A ---> SmPC of [1] of EMA

Concomitant use of EVOTAZ and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Autologous anti-CD19-transduced CD3+ cells [1], corticosteroids ---> SmPC of [1] of EMA

Prophylactic use of systemic corticosteroids may interfere with the activity of Tecartus. Prophylactic use of systemic corticosteroids is therefore not recommended before infusion

Bambuterol [1], corticosteroids ---> SmPC of [1] of eMC

Hypokalemia may result from beta2-agonist therapy and may be potentiated by concomitant treatment with corticosteroids

Barbiturates, corticosteroids

The enzymatic induction may increase the metabolism and decrease the plasma concentrations of corticosteroid

Beclometasone/formoterol/glycopyrronium [1], corticosteroids ---> SmPC of [1] of EMA

Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalaemic effect of beta2-agonists

Benazepril, corticosteroids

Increased blood count alterations

Bendroflumethiazide, corticosteroids

Corticosteroids may exacerbate the hypokalaemia associated with thiazide use.

Besilesomab [1], corticosteroids ---> SmPC of [1] of EMA

The combination may lead to false negative results. Such substances should not be administered together with, or a short time before the injection of besilesomab

Betaxolol, corticosteroids

The sodium and water retention may reduce the antihypertensive effect of betaxolol

Bisacodyl [1], corticosteroids ---> SmPC of [1] of eMC

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of bisacodyl are taken.

Bisoprolol, corticosteroids

Decreased antihypertensive effect due to water and sodium retention

Breast-feeding, corticosteroids

Glucocorticosteroids are excreted in breast milk

Buckthorn berries, corticosteroids

Increased potassium loss

Calcifediol, corticosteroids

Corticosteroids counteract the effects of vitamin D analogues

Calcitriol [1], corticosteroids ---> SmPC of [1] of eMC

A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit it.

Calcium carbonate [1], corticosteroids ---> SmPC of [1] of eMC

Calcium absorption is reduced in patients receiving systemic corticosteroid therapy. This should be taken in to account when patients are receiving concomitant therapy.

Calcium carbonate/cholecalciferol [1], corticosteroids ---> SmPC of [1] of eMC

Concomitant use of glucocorticoids can decrease the effect of vitamin D.

Calcium, corticosteroids

Systemic corticosteroids reduce calcium absorption

Captopril, corticosteroids

The co-administration with systemic corticosteroids may cause decrease of leucocytes, neutropenia and agranulocytosis

Carbamazepine, corticosteroids

Carbamazepine, enzymatic inductor, may decrease the plasma levels of corticosteroid

Carbenoxolone [1], corticosteroids ---> SmPC of [1] of eMC

Hypokalaemic effects of carbenoxolone are enhanced by corticosteroids.

Cardiac glycosides, corticosteroids

The co-administration of cardiac glycosides and drugs that cause potassium and magnesium loss may enhance the effects and adverse reactions of cardiac glycosides

Carvedilol [1], corticosteroids ---> SmPC of [1] of eMC

The antihypertensive effect of carvedilol is decreased due to water and sodium retention.

Cascara bark, corticosteroids

Increased potassium loss

Cemiplimab [1], corticosteroids ---> SmPC of [1] of EMA

The use of systemic corticosteroids or immunosuppressants before starting cemiplimab, except for physiological doses of systemic corticosteroid (≤ 10 mg/day prednisone or equivalent), should be avoided

Certolizumab pegol [1], corticosteroids ---> SmPC of [1] of EMA

Concomitant treatment with methotrexate, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics showed no effect on the pharmacokinetics of certolizumab pegol based on a population pharmacokinetics analysis.

Chloroquine, corticosteroids

The co-administration of chloroquine and corticoids may increase the risk of myopathies and cardiomyopathies

Chlortalidone [1], corticosteroids ---> SmPC of [1] of eMC

The hypokalaemic effect of diuretics may be potentiated by corticosteroids

Cholecalciferol, corticosteroids

There is a functional antagonism between vitamin D analogues (promotion of absorption) and the corticosteroids (inhibition of absorption).

Cilazapril, corticosteroids

Increased blood count alterations

Cladribine [1], corticosteroids ---> SmPC of [1] of EMA

Corticosteroids enhance the risk for severe infections when used in combination with cladribine and should not be given concomitantly with cladribine

Clenbuterol, corticosteroids

The co-administration may increase the effect of clenbuterol

Cobicistat [1], corticosteroids primarily metabolised by CYP3A ---> SmPC of [1] of EMA

Corticosteroids primarily metabolised by CYP3A. Plasma concentrations of these medicinal products may be increased when co-administered with cobicistat, resulting in reduced serum cortisol concentrations.

Corticorelin, corticosteroids

The co-administration of corticorelin with medicinal products that can inhibit its effect should be avoided

Corticosteroids metabolized by CYP3A4, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC o

Concomitant use of Genvoya and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Corticosteroids primarily metabolised by CYP3A [1], elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide --

Concomitant use of Genvoya and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Corticosteroids primarily metabolised by CYP3A [1], elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil ---

Concomitant use of Stribild and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Corticosteroids primarily metabolised by CYP3A, darunavir [2] ---> SmPC of [2] of EMA

Concomitant use of boosted PREZISTA and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Corticosteroids primarily metabolised by CYP3A, darunavir/cobicistat [2] ---> SmPC of [2] of EMA

Concomitant use of REZOLSTA and corticosteroids that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

Corticosteroids [1], coxibs ---> SmPC of [1] of eMC

There is an increased risk of gastrointestinal bleeding when corticosteroids are combined with NSAIDs including COX-2 selective inhibitors.

Corticosteroids [1], phenindione ---> SmPC of [1] of eMC

Corticosteroids potentiate the effect of phenindione

Corticosteroids, coumarin anticoagulants ---> SmPC of [acenocoumarol] of eMC

The co-administration may potentiate the anticoagulant effect of coumarin derivative

Corticosteroids, cyclophosphamide

The co-administration may increase the concentration of cytotoxic metabolites

Corticosteroids, cyclosporine ---> SmPC of [triamcinolone acetonide] of eMC

Monitor for evidence of increased toxicity of cyclosporine when the two are used concurrently.

Corticosteroids, dabrafenib [2] ---> SmPC of [2] of EMA

Interactions with many medicinal products eliminated through metabolism or active transport is expected. These medicinal products are to be avoided or used with caution.

Corticosteroids, deferasirox [2] ---> SmPC of [2] of EMA

The concomitant administration of deferasirox with substances that have known ulcerogenic potential, such as corticosteroids, may increase the risk of gastrointestinal toxicity

Corticosteroids, delapril [2] ---> SmPC of [2] of eMC

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leucopenia.

Corticosteroids, dengue tetravalent vaccine [2] ---> SmPC of [2] of EMA

Dengvaxia should not be administered to subjects receiving immunosuppressive therapies such as chemotherapy or high doses of systemic corticosteroids within 4 weeks prior to vaccination

Corticosteroids, dexibuprofen [2] ---> SmPC of [2] of eMC

The risk of gastrointestinal ulceration may be increased by the concomitant administration of NSAIDs and corticosteroids.

Corticosteroids, dexketoprofen [2] ---> SmPC of [2] of eMC

There is an increased risk of gastrointestinal ulceration or bleeding with corticosteroids

Corticosteroids, diazepam

The enzymatic induction may decrease the plasma levels of diazepam.

Corticosteroids, diclofenac [2] ---> SmPC of [2] of eMC

lncreased risk of gastrointestinal ulceration or bleeding

Corticosteroids, diflorasone

Increased adverse effects

Corticosteroids, digital glycosides ---> SmPC of [metildigoxin] of eMC

Electrolyte imbalance may increase the toxicity of cardiac glycosides

Corticosteroids, digitoxin

Increased effect of digitoxin and risk of digitoxin intoxication due to drug-induced hypokaliemia and hypomagnesemia

Corticosteroids, digoxin [2] ---> SmPC of [2] of eMC

Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin

Corticosteroids, dimethyl fumarate [2] ---> SmPC of [2] of EMA

In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.

Corticosteroids, dinutuximab [2] ---> SmPC of [2] of EMA

It is not recommended to use systemic corticosteroid medicinal products due to possible interference with immune activation which is necessary for the therapeutic action of dinutuximab.

Corticosteroids, disopyramide [2] ---> SmPC of [2] of eMC

Concomitant use of disopyramide with drugs can induce hypokalaemia may reduce the action of the drug, or potentiate proarrhythmic effects

Corticosteroids, diuretics

Effects of diuretics are antagonized by corticosteroids

Corticosteroids, enalapril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Intensified electrolyte depletion, particularly hypokalaemia.

Corticosteroids, epinephrine [2] ---> SmPC of [2] of eMC

Drugs which cause potassium loss (corticosteroids, potassium-depleting diuretic, aminophylline, theophylline) increase the risk of hypokalemia.

Corticosteroids, erlotinib [2] ---> SmPC of [2] of EMA

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based chemotherapy are at increased risk of gastrointestinal perforation

Corticosteroids, estriol [2] ---> SmPC of [2] of eMC

Estriol may possibly increase the pharmacological effects of corticosteroids

Corticosteroids, estrogens ---> SmPC of [deflazacort] of eMC

In patients taking estrogens, corticosteroid requirements may be reduced.

Corticosteroids, ethinyl estradiol

Oestrogens increase plasma concentrations of corticosteroids.

Corticosteroids, etoposide [2] ---> SmPC of [2] of eMC

Etoposide metabolism may be inhibited by corticosteroids in vitro. This may lead to an increase in both efficacy and toxicity of the etoposide.

Corticosteroids, felodipine/ramipril [2] ---> SmPC of [2] of eMC

Increased likelihood of haematological reactions.

Corticosteroids, fenoterol

The co-administration may increase the bronchodilator effect

Corticosteroids, fluphenazine [2] ---> SmPC of [2] of eMC

Phenothiazines may enhance the absorption of corticosteroids

Corticosteroids, flurbiprofen [2] ---> SmPC of [2] of eMC

Corticosteroids with NSAIDs may increase the risk of gastrointestinal ulceration or bleeding with NSAIDs

Corticosteroids, formoterol

Concomitant treatment may potentiate a possible hypokalaemic effect of beta2-agonists.

Corticosteroids, fosinopril

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk of leucopenia.

Corticosteroids, frangula bark

Increased potassium loss

Corticosteroids, furosemide [2] ---> SmPC of [2] of eMC

Diuretic effect anatgonised (sodium retention) and increased risk of hypokalaemia.

Corticosteroids, gestagens

Progestogens increase plasma concentrations of corticosteroids.

Corticosteroids, glatiramer [2] ---> SmPC of [2] of eMC

An increased incidence of injection site reactions has been seen in glatiramer patients receiving concurrent administration of corticosteroids.

Corticosteroids, glibenclamide [2] ---> SmPC of [2] of EMA

Weakening of the blood-glucose-lowering effect

Corticosteroids, glipizide

Elevation in blood glucose.

Corticosteroids, gliquidone

Hyperglycemic reactions may occur as expression of weakening effect of gliquidone with gliquidone is co-administered with corticoids

Corticosteroids, glycerol phenylbutyrate [2] ---> SmPC of [2] of EMA

Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol phenylbutyrate are used concomitantly.

Corticosteroids, glycopyrronium/formoterol [2] ---> SmPC of [2] of EMA

Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible initial hypokalaemic effect of beta2-adrenergic agonists, therefore, caution is advised in their concomitant use

Corticosteroids, glycopyrronium/indacaterol/mometasone [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Corticosteroids, gonadorelin [2] ---> SmPC of [2] of eMC

Corticosteroids may decrease the gonadotropine secretion

Corticosteroids, heparin ---> SmPC of [sodium heparin] of eMC

The anticoagulant effect of heparin may be enhanced by concomitant medication with other drugs affecting platelet function or the coagulation system.

Corticosteroids, herpes zoster vaccine (live) [2] ---> SmPC of [2] of EMA

Immunosuppressive therapy (including high-dose corticosteroids) is contraindicated; however, it is not contraindicated for use in patients who are receiving corticosteroids as replacement therapy, e.g., for adrenal insufficiency

Corticosteroids, histamine dihydrochloride [2] ---> SmPC of [2] of EMA

Systemic steroid must not be used during treatment with histamine dihydrochloride

Corticosteroids, human insulin [2] ---> SmPC of [2] of EMA

Possible increasing in patient's insulin requirement

Corticosteroids, hydralazine [2] ---> SmPC of [2] of eMC

Concurrent treatment of hydralazine may decrease the effects

Corticosteroids, hydrochlorothiazide

Concomitant use of hydrochlorothiazide und amphotericin B (parenteral), carbenoxolone, corticosteroids, corticotropin (ACTH) or stimulant laxatives may intensify the electrolyte disorder, specially hypokaliemia

Corticosteroids, hydroxychloroquine

Concomitant use of hydroxychloroquine and corticosteroids may enhance myopathies or cardiomyopathies

Corticosteroids, hypokalemia

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Corticosteroids, hypokalemia ---> SmPC of [glycopyrronium/indacaterol/mometasone] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists

Corticosteroids, hypokalemia ---> SmPC of [indacaterol/glycopyrronium] of EMA

Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore use with caution

Corticosteroids, ibuprofen [2] ---> SmPC of [2] of EMA

Ibuprofen may increase the risk of gastrointestinal bleeding.

Corticosteroids, immunocyanin

The co-administration may decrease the immunostimulants effect. The combination should be avoided

Corticosteroids, indacaterol [2] ---> SmPC of [2] of EMA

Concomitant hypokalaemic treatment may potentiate the possible hypokalaemic effect indacaterol. Use with caution

Corticosteroids, indapamide [2] ---> SmPC of [2] of eMC

Increased risk of hypokalaemia (additive effect). Decreased antihypertensive effect (water/sodium retention due to corticosteroids).

Corticosteroids, indometacin [2] ---> SmPC of [2] of eMC

The risk of gastro-intestinal bleeding and ulceration associated with NSAIDs is increased when used with corticosteroids

Corticosteroids, infliximab [2] ---> SmPC of [2] of EMA

Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.

Corticosteroids, insulin ---> SmPC of [triamcinolone acetonide] of eMC

Corticosteroids may increase blood glucose; diabetic control should be monitored, especially when corticosteroids are initiated, discontinued, or changed in dosage.

Corticosteroids, insulin glargin [2] ---> SmPC of [2] of EMA

Reduced blood-glucose-lowering effect

Corticosteroids, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA

This substance may reduce the blood-glucose-lowering effect.

Corticosteroids, insulin glulisin [2] ---> SmPC of [2] of EMA

Possible decrease in blood-glucose-lowering activity

Corticosteroids, insulin lispro [2] ---> SmPC of [2] of EMA

Insulin requirements may be increased by medicinal products with hyperglycaemic activity

Corticosteroids, interferon beta-1b [2] ---> SmPC of [2] of EMA

Corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been well tolerated in patients receiving Extavia.

Corticosteroids, iodinated contrast media

Epidural and intrathecal corticosteroids should never be concurrently administered when iodinated contrast media are used, because corticosteroids may promote and affect the signs and symptoms of arachnoiditis

Corticosteroids, iomeprol [2] ---> SmPC of [2] of eMC

Epidural and intrathecal corticosteroids should never be concurrently administered when iodinated contrast media are used, because corticosteroids may promote and affect the signs and symptoms of arachnoiditis

Corticosteroids, ipilimumab [2] ---> SmPC of [2] of EMA

The use of systemic corticosteroids should be avoided before starting ipilimumab treatment, but can be used after starting ipilimumab treatment

Corticosteroids, ketoprofen [2] ---> SmPC of [2] of eMC

Increased risk of gastrointestinal ulceration or bleeding.

Corticosteroids, ketorolac [2] ---> SmPC of [2] of eMC

As with all NSAIDs, caution should be taken when co-administering with corticosteroids because of the increased risk of gastrointestinal ulceration or bleeding

Corticosteroids, lacidipine [2] ---> SmPC of [2] of eMC

Concomitant use of lacidipine and corticoids or tetracosactide might decrease antihypertensive effect.

Corticosteroids, lactitol

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Corticosteroids, lactulose

Lactulose may enhance other drug-induced hypokalemia

Corticosteroids, laxatives

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Corticosteroids, leflunomide [2] ---> SmPC of [2] of EMA

If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, these may be continued after starting leflunomide.

Corticosteroids, lisdexamfetamine [2] ---> SmPC of [2] of eMC

Amfetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.

Corticosteroids, lornoxicam

Corticosteroids increase the risk of gastrointestinal ulceration or bleeding

Corticosteroids, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC

Intensified electrolyte depletion, particularly hypokalaemia.

Corticosteroids, measles vaccine

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, mefloquine

Increased risk of blood count alterations

Corticosteroids, meloxicam

Increased risk of gastrointestinal ulceration or bleeding.

Corticosteroids, methyldopa

Concomitant use of methyldopa and corticosteroids may antagonise the hypotensive effect.

Corticosteroids, metildigoxin

Electrolyte imbalance may increase the toxicity of cardiac glycosides

Corticosteroids, metolazone

The co-administration may increase the risk of hypokaliemia and fluid retention

Corticosteroids, metoprolol [2] ---> SmPC of [2] of eMC

Concomitant use of metoprolol with corticosteroids may result in antagonism of the hypotensive effect.

Corticosteroids, midodrine

The co-administration may potentiate the hypertensive effect

Corticosteroids, mifamurtide [2] ---> SmPC of [2] of EMA

Because mifamurtide acts through stimulation of the immune system, the chronic or routine use of corticosteroids should be avoided during treatment with mifamurtide.

Corticosteroids, mifepristone ---> SmPC of [hydrocortisone] of EMA

The effect of corticosteroids may be reduced for 3-4 days after treatment with mifepristone

Corticosteroids, moexipril

Concomitant administration of systemic corticosteroids with moexipril may lead to an increased risk of leucopenia.

Corticosteroids, moxifloxacin [2] ---> SmPC of [2] of eMC

Moxifloxacin should be used with caution in patients who are taking medication that can reduce potassium levels

Corticosteroids, mumps vaccine

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, muscle relaxants (non-depolarizing) ---> SmPC of [deflazacort] of eMC

In patients treated with systemic corticosteroids, use of non-depolarising muscle relaxants can result in prolonged relaxation and acute myopathy.

Corticosteroids, nabumetone [2] ---> SmPC of [2] of eMC

Increased risk of gastrointestinal ulceration or bleeding

Corticosteroids, nadolol

Decreased antihypertensive effect due to water and sodium retention by corticosteroids

Corticosteroids, naltrexone/bupropion [2] ---> SmPC of [2] of EMA

Caution should be used when prescribing naltrexone/bupropion to patients with predisposing factors that may increase the risk of seizure

Corticosteroids, naproxen [2] ---> SmPC of [2] of eMC

As with all NSAIDs, caution should be taken when co-administering naproxen with corticosteroids because of the increased risk of gastrointestinal ulceration or bleeding

Corticosteroids, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC

There is an increased risk of gastrointestinal bleeding when corticosteroids are combined with NSAIDs including COX-2 selective inhibitors.

Corticosteroids, natalizumab [2] ---> SmPC of [2] of EMA

In Phase 3 MS clinical trials, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection. Short courses of corticosteroids can be used in combination with TYSABRI.

Corticosteroids, nateglinide [2] ---> SmPC of [2] of EMA

Corticosteroids may reduce the hypoglycaemic effect of nateglinide

Corticosteroids, neuroleptics

Antipsychotics may enhance the absorption of corticosteroids

Corticosteroids, nicorandil [2] ---> SmPC of [2] of eMC

Gastrointestinal perforations in the context of concomitant use of nicorandil and corticosteroids have been reported. Caution is advised when concomitant use is considered.

Corticosteroids, nivolumab [2] ---> SmPC of [2] of EMA

The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity.

Corticosteroids, non-potassium-sparing diuretics ---> SmPC of [deflazacort] of eMC

The hypokalaemic effect of diuretics may be potentiated by corticosteroids

Corticosteroids, NSAID ---> SmPC of [methylprednisolone] of eMC

There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs.

Corticosteroids, oral anticoagulants ---> SmPC of [triamcinolone acetonide] of eMC

Corticosteroids may potentiate or decrease anticoagulant action. Patients receiving oral anticoagulants and corticosteroids should therefore be closely monitored.

Corticosteroids, oral antidiabetics ---> SmPC of [triamcinolone acetonide] of eMC

Corticosteroids may increase blood glucose; diabetic control should be monitored, especially when corticosteroids are initiated, discontinued, or changed in dosage.

Corticosteroids, orciprenaline

Concomitant treatment with corticosteroids may enhance the effect of orciprenaline

Corticosteroids, palonosetron [2] ---> SmPC of [2] of EMA

Palonosetron has been administered safely with corticosteroids.

Corticosteroids, pancuronium [2] ---> SmPC of [2] of eMC

Decreased duration of action of pancuronium and the intensity of neuromuscular block.

Corticosteroids, pembrolizumab [2] ---> SmPC of [2] of EMA

The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab

Corticosteroids, perindopril

Increased risk of changes in blood counts

Corticosteroids, perphenazine

Phenothiazines may enhance the absorption of corticosteroids

Corticosteroids, phenobarbital [2] ---> SmPC of [2] of eMC

Phenobarbital enhances the corticosteroid metabolism and its therapeutic effects may be reduced. Therefore it may be necessary to adjust the dose of corticosteroid accordingly

Corticosteroids, phenothiazines ---> SmPC of [perphenazine] of eMC

Phenothiazines may enhance the absorption of corticosteroids

Corticosteroids, phenprocoumon

Weakening of phenprocoumon effect with the use concomitant or prior of corticosteroids

Corticosteroids, phenylbutazone

Increased risk of gastrointestinal ulceration or bleeding.

Corticosteroids, phenytoin

Phenytoin may decrease the plasma concentrations of corticosteroid

Corticosteroids, piroxicam [2] ---> SmPC of [2] of eMC

Increased risk of gastrointestinal ulceration or bleeding

Corticosteroids, poliomyelitis vaccine

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, porfimer [2] ---> SmPC of [2] of EMA

A study investigating pharmacodynamic interactions has demonstrated that corticosteroids given before or concomitant with PDT to decrease formation of strictures may decrease the safety of treatment.

Corticosteroids, potassium citrate/potassium hydrogen carbonate [2] ---> SmPC of [2] of EMA

Periodic monitoring of plasma potassium and ECG is recommended when Sibnayal is administered with medicinal products affected by plasma potassium disturbances due to the potential risk for a pro-arrhythmic effect

Corticosteroids, praziquantel

Decreased plasma concentration of praziquantel

Corticosteroids, pregnancy

Corticosteroids should not be used during pregnancy unless clearly necessary.

Corticosteroids, primidone

Primidone therapy may lead to altered pharmacokinetics in concomitantly administered drugs, whose metabolism may be increased and lead to lowered plasma levels and/or a shorter half-life.

Corticosteroids, propranolol [2] ---> SmPC of [2] of EMA

The adrenal suppression may result in loss of the counter-regulatory cortisol response and increase the risk of hypoglycaemia.

Corticosteroids, pyridostigmine

Peak plasma concentration and AUC of pyridostigmine may decrease by high doses of corticosteroids.

Corticosteroids, quinapril [2] ---> SmPC of [2] of eMC

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leucopenia.

Corticosteroids, radiologic contrasts ---> SmPC of [iomeprol] of eMC

The intrathecal concomitant administration of corticosteroids with contrast agents is contraindicated

Corticosteroids, ramipril [2] ---> SmPC of [2] of eMC

Increased likelihood of haematological reactions

Corticosteroids, repaglinide [2] ---> SmPC of [2] of EMA

Corticosteroids may reduce the hypoglycaemic effect of repaglinide

Corticosteroids, reproterol

The co-administration of corticosteroids and high doses of reproterol may cause intense hypokaliemia

Corticosteroids, retinoids

Corticosteroids should not be used concurrently with retinoids and tetracyclines due to increased intracranial pressure.

Corticosteroids, rifabutin [2] ---> SmPC of [2] of eMC

Rifabutin has been shown to induce the enzymes of the cytochrome P450 3A subfamily and therefore may affect the pharmacokinetic behaviour of drugs metabolised by the enzymes belonging to this subfamily.

Corticosteroids, rifampicin [2] ---> SmPC of [2] of eMC

Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.

Corticosteroids, ritodrine

Risk of acute lung edema. Caution is recommended

Corticosteroids, rocuronium [2] ---> SmPC of [2] of eMC

Long-term concomitant use of corticosteroids and rocuronium in the ICU may result in prolonged duration of neuromuscular block or myopathy

Corticosteroids, romiplostim [2] ---> SmPC of [2] of EMA

Corticosteroids use may be reduced or discontinued when given in combination with romiplostim

Corticosteroids, rubella vaccine

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, salbutamol [2] ---> SmPC of [2] of eMC

There is an increased risk of hypokalaemia if high doses of corticosteroids are given with higher doses of salbutamol.

Corticosteroids, salicylates

The renal clearance of salicylates is increased by corticosteroids and steroid withdrawal may result in salicylate intoxication.

Corticosteroids, salmeterol [2] ---> SmPC of [2] of eMC

Particular caution is advised in acute severe asthma as hypokalaemia may be potentiated by concomitant treatment with glucocorticoids.

Corticosteroids, senna

The co-administration of hypokaliemia-inducer drugs may enhance the potassium loss

Corticosteroids, senna leaf

Increased potassium loss

Corticosteroids, sipuleucel

The co-administration may alter its efficacy and/or safety. The co-administration should be avoided

Corticosteroids, sodium chloride

The co-administration may increase the sodium and chloride retention

Corticosteroids, sodium phenylbutyrate [2] ---> SmPC of [2] of EMA

Corticosteroids may cause the breakdown of body protein and thus increase plasma ammonia levels.

Corticosteroids, sodium picosulfate [2] ---> SmPC of [2] of eMC

The concomitant use of adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of picosulfate are taken.

Corticosteroids, somapacitan [2] ---> SmPC of [2] of EMA

The clearance of compounds metabolised by cytochrome P450 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds.

Corticosteroids, sotalol [2] ---> SmPC of [2] of eMC

With potassium-depleting drugs may occur hypokalaemia, increasing the potential for torsade de pointes

Corticosteroids, spirapril

Increased blood count alterations

Corticosteroids, spironolactone

The combination of corticoids with spironolactone may cause electrolyte depletion, particularly hypokalaemia

Corticosteroids, strong CYP3A4 inhibitors

Co-administered drugs that can inhibit CYP3A4 have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure.

Corticosteroids, tacrolimus [2] ---> SmPC of [2] of EMA

Maintenance doses of corticosteroids reduce tacrolimus blood levels

Corticosteroids, telaprevir

The CYP3A4 induction/inhibition may decrease/increase the plasma levels of telaprevir/ corticosteroid. The concomitant use is not recommended

Corticosteroids, telmisartan [2] ---> SmPC of [2] of EMA

Reduction of the antihypertensive effect

Corticosteroids, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA

Corticosteroids (systemic route) decrease the antihypertensive effect.

Corticosteroids, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA

Medicinal products associated with potassium loss and hypokalaemia: These medicinal products may potentiate the effect of hydrochlorothiazide on serum potassium

Corticosteroids, tenoxicam [2] ---> SmPC of [2] of eMC

As with all NSAIDs, caution should be taken when co-administering tenoxicam and corticosteroids because of the increased risk of GI bleeding.

Corticosteroids, terbutaline [2] ---> SmPC of [2] of eMC

Hypokalaemia may result from beta2-agonist therapy and may be potentiated by concomitant treatment with corticosteroids

Corticosteroids, testosterone ---> SmPC of [testosterone undecanoate] of eMC

The concurrent administration of testosterone or corticosteroids may enhance oedema formation

Corticosteroids, testosterone undecanoate [2] ---> SmPC of [2] of eMC

The concurrent administration of testosterone or corticosteroids may enhance oedema formation

Corticosteroids, tetracyclines

Corticosteroids should not be used concurrently with tetracyclines due to increased intracranial pressure.

Corticosteroids, thiazides ---> SmPC of [deflazacort] of eMC

Corticosteroids may exacerbate the hypokalaemia associated with thiazide use.

Corticosteroids, thiopental

The enzymatic induction by thiopental may decrease the exposition of corticosteroids

Corticosteroids, tolbutamide

Decreased hypoglycaemic effect may occur

Corticosteroids, trandolapril [2] ---> SmPC of [2] of eMC

Systemic corticosteroids may increase the risk of leucopoenia, if used concomitantly with ACE inhibitors.

Corticosteroids, trandolapril/verapamil [2] ---> SmPC of [2] of eMC

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leukopenia

Corticosteroids, triamterene

Effects of diuretics are antagonized by corticosteroids

Corticosteroids, trifluridine

Possible decrease of regenerative power

Corticosteroids, trofosfamide

It has to be taken into account a prior or actual treatment with drugs that are enzyme inducers

Corticosteroids, tuberculosis vaccine

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, urapidil

The co-administration may decrease the hypotensive effect due to water and sodium retention

Corticosteroids, vaccinations ---> SmPC of [prednisone] of eMC

Vaccinations with inactivated vaccines are generally possible. However, it has to be taken into account that the immune response and consequently the success of the vaccination may be impaired with higher doses of glucocorticoids.

Corticosteroids, vaccinations with live organism vaccines

Corticosteroids may decrease the immune response of live vaccines. Disseminated infection may occur

Corticosteroids, vecuronium [2] ---> SmPC of [2] of eMC

Long-term concomitant use of corticosteroids and vecuronium in the ICU may result in prolonged duration of neuromuscular block or myopathy

Corticosteroids, vedolizumab [2] ---> SmPC of [2] of EMA

Vedolizumab administered in patients without concomitant corticosteroid treatment may be less effective for induction of remission in Crohn's disease than in those patients already receiving concomitant corticosteroids

Corticosteroids, vildagliptin [2] ---> SmPC of [2] of EMA

As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

Corticosteroids, vildagliptin/metformin [2] ---> SmPC of [2] of EMA

As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

Corticosteroids, vitamin D ---> SmPC of [calcifediol] of eMC

Corticosteroids counteract the effects of vitamin D analogues

Corticosteroids, xanthines

Hypokalaemic effects of xanthines are enhanced by corticosteroids.

Corticosteroids, xipamide

Increased risk of hypokaliemia (additive effect). Decreased hypotensive effect (water and sodium retention by corticosteroid)

Corticosteroids, zofenopril

Concomitant administration of systemic corticosteroids with ACE inhibitors may lead to an increased risk for leucopenia.